FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution Update on Serious Eye Infections Associated with Soft Contact Lens Use and Contact Lens Solution May 5, 2006. As reported in the MMWR, patients with confirmed cases of Fusarium keratitis have reported using various contact lens cleaning solutions including various types of ReNu […]
Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation
Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves Bausch & Lomb (NYSE:BOL) today asked U.S. retailers to remove ReNu® with MoistureLoc® from their shelves temporarily, and recommended that consumers switch to another lens care solution for the time being, until the investigation of reports of fungal keratitis infections among contact […]
Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation
Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs’ attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When […]
FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients
FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” […]
New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile
New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all […]
FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing Ephedra; Consumers Advised to Stop Using Ephedra Products Immediately
FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing Ephedra; Consumers Advised to Stop Using Ephedra Products Immediately HHS Secretary Tommy G. Thompson today announced that the Food and Drug Administration (FDA) has issued a consumer alert on the safety of dietary supplements containing ephedra and has notified manufacturers of its intent to publish […]